Differential efficacy of dengue vaccine by immune status

The Lancet

Volumn 385, Issue 9979, 2015, Pages 1726-

  Rodriguez Barraquer, Isabel ^a   Mier Y Teran Romero, Luis ^a   Ferguson, Neil ^b   Burke, Donald S ^c   Cummings, Derek A T ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE;

DENGUE; DRUG EFFICACY; HUMAN; IMMUNE STATUS; LETTER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLIC HEALTH; RISK REDUCTION; VACCINATION; VIRUS TRANSMISSION; FEMALE; MALE;

DENGUE; DENGUE VACCINES; FEMALE; HUMANS; MALE;

EID: 84929659825     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60889-3     Document Type: Letter

References (3)

1. MR Capeding, NH Tran, SR Hadinegoro et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial Lancet 384 2014 1358 1365
2. I Rodriguez-Barraquer, L Mier-y-Teran-Romero, DS Burke, DAT Cummings Challenges in the interpretation of dengue vaccine trial results PLoS Negl Trop Dis 7 2013 e2126
3. L Villar, GH Dayan, JL Arredondo-Garcia et al. Efficacy of a tetravalent dengue vaccine in children in Latin America N Engl J Med 373 2015 113 123